This phase II trial is assessing four combination immunotherapies for the treatment of advanced Non-Small Cell (NSC) Lung Cancer.
This trial is treating patients with Non-Small Cell (NSC) Lung Cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer
Bristol-Myers Squibb (BMS)
The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is more effective than Nivolumab by itself in patients with advanced Non-Small Cell lung cancer.
Recruiting Hospitals Read More